GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine,

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults aged 18 and above. An expanded approval will help GSK better compete with rivals such as Merck's mRESVIA and Pfizer's Abrysvo after U.